Nesiritide (acetaat)

Nesiritide (Brain Natriuretic Peptide-32 human) acetate is a recombinant human B-type natriuretic peptide. Nesiritide acetate is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide acetate regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide acetate shows vasodilatory, diuretic, and natriuretic activities. Nesiritide acetate is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury[1][2][3][4][5][6][7].

1684439-46-0

Brain Natriuretic Peptide-32 human (acetate) ; BNP-32 (acetate)

12352209

Calcium Channel; Natriuretic Peptide Receptor (NPR)

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Neuroscience-Neuromodulation

Cardiovascular Disease

CC(O)=O.O=C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(N[C@@H](CSSC1)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CC2=CN=CN2)=O)=O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)CO)=O)CO)=O)CO)=O)CO)=O)([H])[C@@H](C)CC)=O)CCCNC(N)=N)=O)CC(O)=O)=O)CCSC)=O)CCCCN)=O)CCCNC(N)=N)=O)=O)CC3=CC=CC=C3)[C@H]1NC(CNC([C@H](CO)NC(CNC([C@H](CCC(N)=O)NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@H](CCCCN)NC([C@H]4N(CCC4)C([C@@H](N)CO)=O)=O)=O)=O)=O)=O)=O)=O)=O

C145H248N50O44S4

3524.09

[1]Koller KJ, et al. Molecular biology of the natriuretic peptides and their receptors. Circulation. 1992 Oct;86 (4) :1081-8.|[2]Sodi R, et al. B-type natriuretic peptide (BNP) attenuates the L-type calcium current and regulates ventricular myocyte function. Regul Pept. 2008 Nov 29;151 (1-3) :95-105.|[3]Lazar HL, et al. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg. 2009 Sep-Oct;24 (5) :600-5.|[4]Liu S Q, et al. Nesiritide protects endothelial function after balloon-induced trauma in the iliac artery in rabbits. Brazilian Journal of Pharmaceutical Sciences, 2020, 56: e18430.|[5]Liu SQ, et al. Treatment with nesiritide, a recombinant B-type natriuretic Peptide, reduces vascular remodeling following balloon-induced endothelial injuries in rabbits. Tohoku J Exp Med. 2010 Nov;222 (3) :219-23.|[6]Liu SQ, et al. Recombinant B-type natriuretic peptide nesiritide attenuates vascular remodelling by reducing plasma aldosterone in rabbits. Heart Lung Circ. 2012 Sep;21 (9) :551-5.|[7]Hobbs RE, et al. Therapeutic potential of nesiritide (recombinant b-type natriuretic peptide) in the treatment of heart failure. Expert Opin Investig Drugs. 1999 Jul;8 (7) :1063-72.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P0003A/

Peptides

Phase 4